Heart Rate Lowering for Coronary CTA with Ivabradine in End-Stage Liver Disease

Rishabh Tandon; Dzhalal Agakishiev; Rebecca L Freese; Julie Thompson; Prabhjot S Nijjar

doi:10.1148/ryct.230402

Heart Rate Lowering for Coronary CTA with Ivabradine in End-Stage Liver Disease

Radiol Cardiothorac Imaging. 2024 Jun;6(3):e230402. doi: 10.1148/ryct.230402.

Authors

Rishabh Tandon¹, Dzhalal Agakishiev¹, Rebecca L Freese¹, Julie Thompson¹, Prabhjot S Nijjar¹

Affiliation

¹ From the Department of Medicine, Cardiovascular Division, University of Minnesota Medical Center, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455 (R.T., P.S.N.); Department of Medicine (D.A.) and Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition (J.T.), University of Minnesota Medical School, Minneapolis, Minn; and Clinical and Translational Science Institute, Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, Minn (R.L.F.).

Abstract

In a study of 282 patients with end-stage liver disease undergoing coronary CT angiography, administration of a single dose of ivabradine (up to 15 mg) was found to be safe and effective at heart rate lowering.

Keywords: CT Angiography; Cardiac; Coronary Arteries; Ivabradine.

MeSH terms

Aged
Benzazepines / pharmacology
Benzazepines / therapeutic use
Cardiovascular Agents / pharmacology
Cardiovascular Agents / therapeutic use
Computed Tomography Angiography
Coronary Angiography*
Coronary Artery Disease / diagnostic imaging
Coronary Artery Disease / drug therapy
End Stage Liver Disease* / drug therapy
Female
Heart Rate* / drug effects
Humans
Ivabradine* / pharmacology
Ivabradine* / therapeutic use
Male
Middle Aged

Substances

Ivabradine
Cardiovascular Agents
Benzazepines

Grants and funding

UL1 TR002494/TR/NCATS NIH HHS/United States